SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
NCT03409250
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Choroidal Neovascularization
Age Related Macular Degeneration
Interventions
DRUG:
Ranibizumab, Lucentis
Sponsor
Vista Klinik